Accuphase revenue 370 million yuan in the first half gross profit of 258 million yuan-www.yngbzx.cn

Accuphase revenue 370 million yuan in the first half gross profit of 258 million yuan a thousand thousand shares hot column capital flows on stock diagnosis the latest rating simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future? Sina Hong Kong stocks launched "Hong Kong stocks are not attractive" big discussion, with a rational and constructive attitude, welcome to pay attention to Hong Kong stocks, people concerned about the capital market, together with Hong Kong stocks for advice and suggestions, and conspiracy of Hong Kong stock market tomorrow. Please to hkstock_biz@sina. In August 29th, (06896) announced the first half of 2016 concise financial report (not audited), the indicators continued to grow, of which revenue grew 6.3% to 370 million 600 thousand yuan, gross profit grew 2.3% to 258 million 400 thousand yuan. During the reporting period, Jin Sangzi tablet revenue growth to 3.267 billion yuan, a year-on-year growth of more than 2015 slightly; Jin Sangzi throat treasure series products revenue increased to 2090 million yuan, representing a growth of 19.4% 2015 in the same period; herb beverage and ginkgo leaf and other income increased to 2300 million yuan, representing a growth of 411.1% 2015 in the same period. At present, Accuphase established a comprehensive distribution network, through a combination of online and offline, covering all the provinces, autonomous regions and municipalities directly under the central government. At the same time, continue to expand overseas markets. For example, the introduction of an American agent with a sound and large distribution network and Internet channels in North America has reached the intention of cooperation with the famous India pharmaceutical company with over 600 thousand retail pharmacies at all levels. At present, Accuphase group products have been involved in a number of overseas markets including the United States, Canada, EU, Australia, Southeast Asia and the Middle East. As a leading manufacturer of lozenges, since the 1994 launch of Accuphase tablet, with marketing ability and strong distribution network, become known to every family of well-known brands. Report of the third party authority Euromonitor International, Jin Sangzi Runhou tablet products (including Jin Sangzi and Jin Sangzi throat throat treasure Series) occupy the largest market share in China, about 25.8%. At the beginning of this year, and entered the field of food beverage and the introduction of Accuphase herb beverage caused widespread concern in the market and consumers. Future Ltd will continue to seek to consolidate its leading position in Runhou tablet market, continues to expand its China in medicine and food market. Most importantly, the company will strive to enhance capacity, expand product portfolio and enhance R & D capabilities, strengthen its food and other pharmaceutical business, and promote synergies between different product segments. Enhance brand awareness through effective targeted marketing, and continue to expand its distribution network, upgrade related infrastructure and use its existing distribution network to promote different products. The industry believes that, as the China Runhou tablet enterprises, Accuphase’s golden throat tablets and golden throat products by the market and consumers. On the introduction of new herbal beverage products

金嗓子上半年营收3.7亿元 毛利润2.58亿元 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 新浪港股APP:实时行情 独家内参   港股还值不值得投资?出现了什么问题?未来出路在哪里?新浪港股发起“港股还有没有吸引力”大讨论,以理性、建设性的态度,欢迎关注港股、关注资本市场的人士,一起为港股建言献策,共谋港股市场的明天。来稿请至hkstock_biz@sina 。   8月29日,金嗓子(06896)公布2016年上半年简明财务报告(未经审核),各项指标均保持持续增长,其中收入同比增长6.3%至3.706亿元,毛利润同比增长2.3%至2.584亿元。   报告期内,金嗓子喉片的收入增长至3.267亿元,比2015年同期稍有增长;金嗓子喉宝系列产品的收入增长至2090万元,较2015年同期增长19.4%;草本植物饮料及银杏叶片等其他收入增长至2300万元,较2015年同期增长411.1%。   目前,金嗓子建立了全面的分销网络,通过线上线下结合,覆盖了国内所有省市、自治区及直辖市。与此同时,不断扩展海外市场。如在北美地区引入拥有健全而庞大的经销网络及互联网渠道的美国代理商,与拥有超过60万间各级零售药店的著名印度医药公司达成合作意向。目前,金嗓子集团产品已涉足包括美国、加拿大、欧盟、澳洲、东南亚及中东等地区在内的多个海外市场。   作为国内领先的润喉片制造商,自1994年推出金嗓子喉片,通过强大的市场推广能力及分销网络,成为家喻户晓的知名品牌。第三方权威机构欧睿国际的报告显示,金嗓子润喉片产品(包括金嗓子喉片和金嗓子喉宝系列产品)在国内占据最大的市场份额,约为25.8%。今年年初,又进入食品饮料领域并推出金嗓子草本植物饮料引发市场与消费者的广泛关注。   未来公司将继续寻求巩固其于润喉片市场的领先地位,继续扩大其于中国药品及食品市场的市场份额。最重要的是,公司将致力提升产能、扩大产品组合及增强研发能力,加强其食品及其他药品业务并促进不同产品分部间的协同作用。透过有效的定向市场推广提高品牌知名度,及继续扩大其分销网络、提升相关基础设施及利用其现有分销网络以推广不同产品。   业内人士认为,作为中国润喉片的龙头企业,金嗓子的金嗓子喉片及金嗓子喉宝系列产品备受市场及消费者的喜爱。而草本植物饮料新产品的推出,更是让经典的金嗓子再添新光彩。凭借金嗓子长久以来的品牌资本积累,新产品推出元年的良好契机,配合深耕国内市场、推广国际化布局的市场布局策略,金嗓子未来发展必会有新的飞跃。 进入【新浪财经股吧】讨论相关的主题文章: